Credit Suisse AG raised its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 169.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 144,368 shares of the biopharmaceutical company’s stock after buying an additional 90,748 shares during the period. Credit Suisse AG’s holdings in TG Therapeutics were worth $1,682,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of TGTX. FMR LLC boosted its position in shares of TG Therapeutics by 70.2% in the first quarter. FMR LLC now owns 6,451,713 shares of the biopharmaceutical company’s stock valued at $75,162,000 after buying an additional 2,660,949 shares during the period. Vanguard Group Inc. boosted its position in shares of TG Therapeutics by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,790,583 shares of the biopharmaceutical company’s stock valued at $20,860,000 after buying an additional 246,404 shares during the period. Jennison Associates LLC purchased a new position in shares of TG Therapeutics during the first quarter valued at about $16,034,000. Columbus Circle Investors boosted its position in shares of TG Therapeutics by 29.3% in the first quarter. Columbus Circle Investors now owns 1,004,421 shares of the biopharmaceutical company’s stock valued at $11,702,000 after buying an additional 227,722 shares during the period. Finally, State Street Corp boosted its position in shares of TG Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 679,115 shares of the biopharmaceutical company’s stock valued at $3,157,000 after buying an additional 42,760 shares during the period. Hedge funds and other institutional investors own 45.68% of the company’s stock.

Shares of TG Therapeutics, Inc. (TGTX) traded up 12.38% during trading on Friday, hitting $11.35. The company had a trading volume of 1,871,116 shares. TG Therapeutics, Inc. has a 12-month low of $4.10 and a 12-month high of $15.35. The stock’s market cap is $707.22 million. The firm has a 50 day moving average of $10.93 and a 200 day moving average of $10.00.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. On average, analysts forecast that TG Therapeutics, Inc. will post ($1.78) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/13/credit-suisse-ag-has-1-68-million-position-in-tg-therapeutics-inc-nasdaqtgtx.html.

Several equities analysts have recently issued reports on TGTX shares. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research report on Monday, May 1st. BidaskClub cut TG Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. Jefferies Group LLC started coverage on TG Therapeutics in a research report on Tuesday, April 25th. They set a “buy” rating and a $23.00 price target on the stock. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. TG Therapeutics presently has an average rating of “Buy” and an average price target of $23.67.

In other news, CFO Sean A. Power sold 59,976 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the transaction, the chief financial officer now directly owns 477,464 shares in the company, valued at approximately $5,295,075.76. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 16.70% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.